Results 231 to 240 of about 362,216 (339)

Impact of perinatal hypertonic NaCl access on adult offspring's sodium intake and angiotensin and vasopressin systems under hypertension model. [PDF]

Sci Rep
Porcari CY, Lencina CA, Amigone JL, Antunes-Rodrigues J, Caeiro XE, Godino A.   +5 more
europepmc   +1 more source

An unexpected ally in heart failure treatment: Unlocking the potential of sodium‐glucose cotransporter 2 inhibitors across patient subpopulations

ESC Heart Failure, EarlyView.
Sander Trenson, Mateusz Sokolski
wiley   +1 more source

The effect of trimetazidine on cardiac haemodynamics and mitochondrial function in wild‐type transthyretin amyloidosis

ESC Heart Failure, EarlyView.
Abstract Aims Wild‐type transthyretin cardiac amyloidosis (ATTRwt) is a cardiomyopathy causing myocardial hypoperfusion and impaired cardiac mitochondrial function. Trimetazidine is an antianginal agent used in patients with stable angina pectoris, which improves cardiac contractility and mitochondrial function.
Bertil Thyrsted Ladefoged, Anders Lehmann Dahl Pedersen, Anne Mette Dybro, Tor Skibsted Clemmensen, Julian Gillmore, Steen Hvitfeldt Poulsen   +5 more
wiley   +1 more source

Prognostic Implications of Guideline-Directed Medical Therapy for Heart Failure in Functional Mitral Regurgitation: A Systematic Review and Meta-Analysis. [PDF]

Diagnostics (Basel)
Anastasiou V, Papazoglou AS, Daios S, Moysidis DV, Tsiartas E, Didagelos M, Dimitriadis K, Karamitsos T, Giannakoulas G, Tsioufis K, Ziakas A, Kamperidis V.   +11 more
europepmc   +1 more source

The progressive pressor response to angiotensin in the rabbit

, 1967
C. J. Dickinson, Rong Yu
openalex   +2 more sources

Biomarkers in heart failure: Traditional and emerging indicators for prognosis

ESC Heart Failure, EarlyView.
Arnold Péter Ráduly, László Nagy, Beáta Bódi, Zoltán Papp, Attila Borbély   +4 more
wiley   +1 more source

Long‐term outcomes of apixaban as main anticoagulant in patients with HeartMate 3 left ventricular assist devices

ESC Heart Failure, EarlyView.
Abstract Aims HeartMate 3 (HM3) left ventricular assist devices (LVADs) offer improved haemocompatibility‐related outcomes for end‐stage heart failure patients, facilitating the exploration of alternative anticoagulation therapies beyond warfarin.
Jennifer Jdaidani, Mahmoud Shadi, Nnedi Asogwa, Jennifer Winik, Dora Rossi, Christina Saikus, Maria D. Avila, Geurys R. Rojas‐Marte   +7 more
wiley   +1 more source

Oxidized low-density lipoprotein potentiates angiotensin II-induced Gq activation through the AT1-LOX1 receptor complex. [PDF]

Elife
Ihara J, Huang Y, Takami Y, Nozato Y, Takahashi T, Kakino A, Wang C, Wang Z, Guo Y, Liu W, Yin N, Ohara R, Fujimoto T, Yoshida S, Hongyo K, Koriyama H, Akasaka H, Takeshita H, Sakai S, Inoue K, Isaka Y, Rakugi H, Sawamura T, Yamamoto K.   +23 more
europepmc   +1 more source

Real‐world comparative effectiveness of sacubitril/valsartan versus RAS inhibition alone in patients with de novo heart failure

ESC Heart Failure, EarlyView.
Abstract Aims Large‐scale, real‐world data on early initiation of sacubitril/valsartan in patients newly diagnosed (de novo) with HF with reduced ejection fraction (HFrEF) are limited. We examined the effectiveness of sacubitril/valsartan versus angiotensin‐converting enzyme inhibitor (ACEi)/angiotensin receptor blocker (ARB) on all‐cause and cause ...
Ankeet S. Bhatt, Muthiah Vaduganathan, Barada P. Jena, Sylwia Suminska, Carlos Eid, Heike Schwende, Michele Senni   +6 more
wiley   +1 more source

Adult-onset Bartter syndrome type IV B with ACTH secreting pituitary microadenoma. [PDF]

J Bras Nefrol
Mathew GG.
europepmc   +1 more source